Fig. 3.

NorUDCA exerts strong systemic immunometabolic modulatory properties in LCMV clone 13 model.

(A) Representative plots of virus-specific CD8⁺ T cells from peripheral blood and spleen. Cells recognizing the LCMV-GP33 peptide in the context of MHC class I presentation are labeled as GP33⁺. Quantitative analysis is shown alongside. (B) pRPS6^Ser235/236 expression on blood CD8⁺ T cells. Quantitative analysis is shown alongside. (C) Representative high-power field multicolor immunofluorescence staining of CD3/CD8 and CD3/pRPS6^Ser235/236 (lower) of lung slides of indicated groups. Data are pooled from 3 independent experiments. At least 3 biologically independent animals were used per group during experiments. Quantitative data are presented as mean±SE. p values were calculated by one-way ANOVA corrected with Tukey post-hoc test. ∗p <0.05, ∗∗p <0.01, ∗∗∗p <0.001, ∗∗∗p <0.001, ∗∗∗∗p <0.0001. LCMV, lymphocytic choriomeningitis virus; NorUDCA, 24-norursodeoxycholic acid; Rapa, rapamycin.